In vitro activity of newer β-lactam/β-lactamase inhibitor combinations, cefiderocol, plazomicin and comparators against carbapenemase-producing Klebsiella pneumoniae isolates

References

• Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019; Available at https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
   Google Scholar
• Bartsch SM, McKinnell JA, Mueller LE, et al. Potential economic burden of carbapenem-resistant enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect. 2017;23(1):48.e9-48–e16.
   Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net). Annual epidemiological report for 2020. https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-eueea-ears-net-annual-epidemiological-report-2020.pdf.
   Google Scholar
• Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785–796.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Galani I, Papoutsaki V, et al. Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies. Expert Rev anti Infect Ther. 2022;20(1):53–69.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Carrara E, Conti M, et al. Role of new antibiotics for KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2021;76(Suppl 1):i47–i54.
   PubMedGoogle Scholar
• Yahav D, Giske CG, Grāmatniece A, et al. New β-Lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev. 2020;34(1):e00115-20.
   PubMed Web of Science ®Google Scholar
• Poirel L, Walsh TR, Cuvillier V, et al. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119–123.
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing (EUCAST). Guidance document on broth microdilution testing of cefiderocol. EUCAST; 2020. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Cefiderocol_MIC_testing_EUCAST_guidance_document_201217.pdf.
   Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation for MICs and zone diameters: version 10.0, valid from 2022-01-01. 2022. EUCAST, Basel, Switzerland.
   Google Scholar
• FDA. Antibacterial susceptibility test interpretive criteria; 2019. https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Galani I, Karaiskos I, Karantani I, et al. Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016. Euro Surveill. 2018;23(31):1700775.
   PubMedGoogle Scholar
• Maraki S, Mavromanolaki VE, Magkafouraki E, et al. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates. Infection. 2022;50(2):467–474.
   PubMed Web of Science ®Google Scholar
• Rossolini GM, Stone GG. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015–2017). Int J Antimicrob Agents. 2020;56(3):106111.
   PubMed Web of Science ®Google Scholar
• Galani I, Souli M, Nafplioti K, Study Collaborators, et al. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015–2016. Eur J Clin Microbiol Infect Dis. 2019;38(6):1143–1150.
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883-17.
   PubMed Web of Science ®Google Scholar
• Shields RK, McCreary EK, Marini RV, et al. Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2020;71(3):667–671.
   PubMed Web of Science ®Google Scholar
• Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799–1808.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Wang R, et al. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18–27.
   PubMed Web of Science ®Google Scholar
• Sun D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(12):e01694-17.
   PubMed Web of Science ®Google Scholar
• Findlay J, Rens C, Poirel L, et al. In vitro mechanisms of resistance development to imipenem-relebactam in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2022;66(10):e0091822.
   PubMed Web of Science ®Google Scholar
• Galani I, Karaiskos I, Souli M, et al. Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece. Euro Surveill. 2020;25(3):2000028.
   PubMedGoogle Scholar
• Jacobs MR, Good CE, Hujer AM, et al. ARGONAUT II study of the in vitro activity of plazomicin against carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(5):e00012-20.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Avial I, Pena I, Picazo JJ, et al. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing enterobacteriaceae strains. Int J Antimicrob Agents. 2015;46(6):616–621.
   PubMed Web of Science ®Google Scholar
• Connolly LE, Riddle V, Cebrik D, et al. A multicenter, randomized, Double-Blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis. Antimicrob Agents Chemother. 2018;62(4):e01989-17.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380(8):729–740.
   PubMed Web of Science ®Google Scholar
• McKinnell JA, Dwyer JP, Talbot GH, et al. Plazomicin for infections caused by carbapenem-resistant enterobacteriaceae. N Engl J Med. 2019;380(8):791–793.
   PubMed Web of Science ®Google Scholar
• Sato T, Yamawaki K. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin Infect Dis. 2019;69(Suppl 7):S538–S543.
   PubMedGoogle Scholar
• Zhanel GG, Golden AR, Zelenitsky S, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs. 2019;79(3):271–289.
   PubMed Web of Science ®Google Scholar
• Hackel MA, Tsuji M, Yamano Y, et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother. 2018;62(2):e01968–17.
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Sadouki Z, Vickers A, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against multidrug-resistant gram-negative bacteria. Antimicrob Agents Chemother. 2020;64(12):e01582–20.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–240.
   PubMed Web of Science ®Google Scholar